Anjali Bahot

Ms. Anjali Bahot

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
ABAnjali Bahot
Anjali Bahot
GSGopinath Sekar
Gopinath Sekar
MBMahima Bansode
Mahima Bansode
KKKratika Khunteta
Kratika Khunteta
Birandra K. K SinhaBirandra K. K Sinha
Birandra K. K Sinha
In recent years, the emergence of cancer drug resistance has been one of the crucial tumor hallmarks that are supported by the level of genetic heterogeneity and complexities at cellular levels. Oxidative stress, immune evasion, metabolic reprogramming, overexpression of ABC transporters, and stemness are among the several key contributing molecular and cellular response mechanisms. Topo-active drugs, e.g., doxorubicin and topotecan, are clinically active and are utilized extensively against a wide variety of human tumors and often result in the development of resistance and failure to therapy. Thus, there is an urgent need for an incremental and comprehensive understanding of mechanisms of cancer drug resistance specifically in the context of topo-active drugs. This review delves into the intricate mechanistic aspects of these intracellular and extracellular topo-active drug resistance mechanisms and explores the use of potential combinatorial approaches by utilizing various topo-active drugs and inhibitors of pathways involved in drug resistance. We believe that this review will help guide basic scientists, pre-clinicians, clinicians, and policymakers toward holistic and interdisciplinary strategies that transcend resistance, renewing optimism in the ongoing battle against cancer.

1 October 2023 in Epigenomics
Verified
Journal Article
Closed access
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
SSSachin Sarode
Sachin Sarode
ABAnjali Bahot
Anjali Bahot
GSGopinath Sekar
Gopinath Sekar
The emerging understanding of the super-complex and heterogeneous nature of tumor is well supported by metabolic reprogramming, leading survival advantages. Metabolic reprogramming contributes to t... Plain language summary Cancer cells are known to show complexity and resistance to treatment, including chemotherapies and radiation therapies. The ability of cancer cells to overcome effects of an... Tweetable abstract Among various mechanisms adopted by cancer cells, acetylation of amino acids is considered a key to metabolic reprogramming in drug resistance. Exploring mimetics of acetylated a...

1 August 2025 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
GSGopinath Sekar
Gopinath Sekar
ABAnjali Bahot
Anjali Bahot
MBMahima Bansode
Mahima Bansode
APAnushka Phadnis
Anushka Phadnis
SSSachin Sarode
Sachin Sarode
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
Vitamin C plays a significant role in various physiological functions. Humans depend on external sources of vitamin C due to the loss of the L-gulono-γ-lactone oxidase (GULO) gene that contributes to the synthesis of vitamin C. During the evolutionary loss of the GULO gene, physical, chemical, and biological factors were different from the present environmental settings. Besides the evolutionary genetic loss of the GULO gene, there is a gap in the insightful discussion on the potential implications of the non-functional GULO gene towards the predisposition of humans to cancer that faces hostile and carcinogenic environments. Various methods by which vitamin C modulates cellular processes related to cancer, including DNA repair, epigenetic changes, and redox balance, are discussed. Furthermore, we present experimental and clinical evidence indicating that vitamin C deficiency promotes tumor growth, metastasis, and therapy resistance, emphasizing its potential as a cancer phenotypic modulator. Therapeutic implications of restoring vitamin C levels in cancer treatment range from improving the efficacy of conventional medicines to exploiting metabolic vulnerabilities in tumors. The relevance of assessing vitamin C status in cancer patients and the basis for additional research into vitamin C supplementation as an adjuvant therapy is emphasized. This paper presents a comprehensive overview of the implications associated with the functional deficiency of the GULO gene in human subjects exhibiting diverse tumor hallmarks, encompassing ECM remodeling, hypoxia, epigenetic reprogramming, oxidative stress, and drug responsiveness.